Lyra Medical has developed a new implant for the surgical treatment of pelvic organ prolapse (POP). The proprietary, patented self-retaining support (SRS) technology eliminates the need for complex anchoring techniques that compromise the safety and long-term success of existing treatments solutions.
Lyra’s technology mimics the natural anatomy and restores pelvic organs to their functional and physiological location. It represents a new anchorless method that significantly improves current transvaginal mesh (TVM) solutions. SRS technology was developed to eliminate the high complication rate associated with current anchored TVMs and reverse the low success rate associated with native-tissue repair.
The SRS Implant has been proven in clinical trials to deliver exceptional safety and long-term efficacy through a simple and well-known procedure. The procedure can be performed by any trained gynecologist or urologist and provides an excellent solution even to the most severe POP cases.
The company’s SRS technology is presently being applied for the treatment of advanced anterior vaginal wall prolapse. The support platform may be applicable in other pelvic organ disorder conditions, such as rectocele and urinary incontinence, as well as other clinical areas. In all these areas, there is an acute need for therapeutic solutions that deliver long-term safety and efficacy.
Company’s Keywords:
<7
<
<